Comments
Biocon Biologics Ltd, a subsidiary of Biocon Ltd, has received a European Union (EU) goods manufacturing practice (GMP) certificate from the Health Products Regulatory Authority (HPRA), Ireland, for its new monoclonal antibodies (mAbs) drug substance manufacturing facility (B3) at Biocon Park, Bengaluru, following a GMP inspection in April 2022.
“The 340,000 square feet facility, will enhance our capability to manufacture drug substances of our mAbs portfolio and will enable us to serve patients across the globe. This facility integrates manufacturing suites, analytical testing laboratories, and warehousing,” said a spokesperson from Biocon Biologics.
In 2021, it was awarded the Facility of the Year Award (FOYA) with an Honorable Mention, by the International Society for Pharmaceutical Engineering (ISPE).
The good manufacturing practice certificate (GMP) describes the minimum standards that pharmaceutical manufacturers must meet in their production processes.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.